Interleukin 8 (IL-8) Selectively Inhibits Immunoglobulin E Production Induced by IL-4 in Human B Cells

By H. Kimata, A. Yoshida, C. Ishioka, I. Lindley,* and H. Mikawa

From the Department of Pediatrics, Kyoto University Hospital, Kyoto 606, Japan; and the *Sandoz Research Institute, A-1235 Vienna, Austria

Summary

The effect of interleukin 8 (IL-8) on IL-4-induced immunoglobulin E (IgE) production was studied. IL-4 induced IgE and IgG4 production by tonsillar mononuclear cells (MNC) without affecting IgM, IgG1, IgA, IgG2, or IgG3 production. IL-8 inhibited IL-4-induced IgE and IgG4 production, whereas it had no effect on IgM, IgG1, IgA, IgG2, and IgG3 production. The inhibitory effect by IL-8 was specific, since it was blocked by anti-IL-8 mAb, but not by control IgG1. Although interferon γ (IFN-γ) also inhibited IgE and IgG4 production by MNC stimulated with IL-4, the inhibitory effect of IL-8 was not mediated by IFN-γ, since the IL-8-induced inhibition could not be blocked by anti-IFN-γ mAb. Furthermore, anti-IL-8 mAb had no effect on IFN-γ-induced inhibition. Moreover, addition of IL-5 or IL-6 did not reverse IL-8-induced inhibition of IgE production. In contrast to these observations with MNC, IL-4 failed to induce IgE and IgG4 production by purified B cells. However, combined treatment of purified B cells with IL-4 and anti-CD40 antibody resulted in IgE but not IgG4 production. IL-8 inhibited this IgE production without affecting IgM, IgG1, IgG2, IgG3, IgG4, or IgA production, whereas IFN-γ, IFN-α, or prostaglandin E2 (PGE2) failed to do so. These results indicate that IL-8 antagonizes IL-4-induced IgE production by directly affecting B cells through a specific mechanism that is different from IFN-γ, IFN-α, or PGE2.

IgE production has been shown to be regulated by many factors in various in vitro systems. In mononuclear cells (MNC), IL-4 induces IgE production, which can be inhibited by IFN-α, IFN-γ, or prostaglandin E2 (PGE2) (1), and enhanced by IL-5 or IL-6 (2, 3). IL-4 has also been shown to inhibit IFN-γ synthesis or release of PGE2 (4, 5), indicating mutual interaction of these factors. In contrast, in purified B cells, IL-4 alone cannot induce IgE production. However, stimulation of purified B cells with IL-4 and anti-CD40 ab induces IgE production, which is IFN-α- and IFN-γ-independent (6–8). We have previously reported that soluble CD23 enhances IgE production without affecting cell growth in the human IgE-producing cell line AF-10, which is a subclone of U266 (9). We have also found that IgE production is regulated by erythropoietin or disodium cromoglycate in an IFN-α- and IFN-γ-independent, but in a T cell- and monocyte-dependent fashion (10, 11).

IL-8 was initially characterized and cloned as a neutrophil chemotactic and activating agent (12). However, it has subsequently been shown that IL-8 is also chemotactic for T cells, induces histamine release from IL-3–primed basophils, and inhibits neutrophil adhesion to endothelium (13–15). A report that IL-4 inhibits IL-8 production from monocytes (16) prompted us to study the effect of IL-8 on IL-4–induced IgE production to see whether there was mutual interaction. We demonstrate that IL-8 inhibits IgE production in MNC and in purified B cells in an IFN-α- and IFN-γ-independent fashion.

Materials and Methods

Reagents. The following recombinant human cytokines were kindly provided by the companies as described previously (10, 11): IL-4 (Ono Pharmaceutical Company, Osaka, Japan); IL-5 (Suntory Research Center, Osaka); IL-6 (kind gift from Drs. T. Hirano and T. Kishimoto, Institute for Molecular and Cellular Biology, Osaka); and IFN-α and IFN-γ (Takeda Chemical Industries, Osaka). Human rIL-8 which has the same neutrophil-activating potency as the natural product isolated from LPS-stimulated MNC and immunosorbent purified mouse IgG1 monoclonal anti-IL-8 ab (4G9/A5/A7) were obtained from Sandoz Research Institute (Vienna, Austria) (12, 14). Chemotactic assay for fresh human neutrophils showed that activity was detected at 0.06–1.7 μg/ml, with maximal activity at 0.2 μg/ml. Mouse IgM anti-CD40 antibody (MA6), mouse IgG3 anti–human IFN-γ ab and control mouse IgG1 were purchased from Cosmo Bio Co. (Tokyo, Japan). PGE2 was purchased from Nakalai Chemicals (Kyoto, Japan).

Cell Cultures. Tonsillar MNC from nonatopic donors were cultured (2 × 105/0.2 ml/well) in 96-well U-bottomed microtiter
plates (Costar Corp., Cambridge, MA) for 14 d in RPMI 1640 medium (M. A. Bioproducts, Walkersville, MD) containing 10% FCS (Irvine Scientific, Santa Ana, CA), 2 mM l-glutamine, 50 U/ml penicillin, and 50 μg/ml streptomycin, and stimulated with IL-4 (800 U/ml) and various factors as described in Results. Highly purified B cells were obtained by SRBC rosetting, followed by l-leucine methyl ester incubation as described previously (11). Purified B cell fractions contained <1% CD3+ T cells, <1% CD11+ monocytes, <1% CD16+ NK cells, and >98% CD20+ B cells. Purified B cells were cultured (10^5 cells/0.2 ml/Well) with various factors for 14 d. Control cultures for the evaluation of preformed Ig were carried out in the presence of cycloheximide (100 μg/ml). The amount of IgE, IgG subclasses, IgM, and IgA in the supernatants were determined by ELISA (9, 11).

Results

The effect of IL-8 on IL-4-induced IgE production was studied in MNC. As shown in Fig. 1A, IL-8 inhibited IgE production in a dose-dependent fashion. IL-8 also inhibited IL-4-induced IgG4 production. In contrast, IL-8 had no effect on IgM, IgG1, IgA, IgG2, and IgG3 production (Fig. 1B). Ig production by MNC in the absence of IL-4 were as follows: IgE <0.2 ng/ml; IgG1 705 ± 128 ng/ml; IgG2 217 ± 59 ng/ml; IgG3 108 ± 25 ng/ml; IgG4 3.2 ± 0.5 ng/ml; IgM 910 ± 129 ng/ml; and IgA 528 ± 91 ng/ml (mean ± one SD from two experiments). IL-8 did not affect production of these Igs in the absence of IL-4.

We next studied the effect of delayed addition of IL-8 on IL-4–induced IgE and IgG4 production. As shown in Fig. 2, IL-8 inhibited IgE and IgG4 production only when added at the initiation of the 14-d culture. After 1 d of culture, IL-8 had no effect on IgE and IgG4 production. These results suggested that IL-8 interfered with IL-4 stimulation at the early stage, and that the inhibition was not due to simple cytotoxic effects.

Specificity of the IL-8 effect is documented in Table 1. Inhibition of IgE and IgG4 production by IL-8 was blocked by anti–IL-8 mAb, but not by control IgG1, although anti–IL-8 did not affect IgE and IgG4 production in the absence of IL-8. IFN-γ also inhibited IgE and IgG4 production in IL-4–stimulated cultures, and anti–IFN-γ mAb completely blocked the inhibition by IFN-γ. However, inhibition by IL-8 was not mediated by IFN-γ, since the IL-8 effect was not blocked by anti–IFN-γ mAb, and conversely, the IFN-γ effect was not blocked by anti–IL-8 mAb. Moreover, addition of IL-5 or IL-6 did not reverse IL-8–induced inhibition of IgE production (Table 1).

We also studied the effect of IL-8 on IgE production by purified B cells. It has been reported that stimulation of IL-4 and anti-CD40 ab induces IgE production by purified B cells in the absence of T cells (6–8). Thus, highly purified B cells were stimulated with IL-4 and anti-CD40 ab, and IL-8 and/or other factors were added. As shown in Table 2, IL-8 had no effect on IgE, IgM, IgA, and IgG4 production by B cells without stimuli. Stimulation of IL-4 and anti-CD40 induced IgE but not IgM, IgA, or IgG4 production. IgG1, IgG2, or IgG3 production was also not induced (data not shown). Addition of IFN-α, IFN-γ, or PGE2, which inhibits IL-4–induced IgE production by MNC (1), did not inhibit IgE production by purified B cells.

![Figure 1](image1.png)

**Figure 1.** Effect of IL-8 on Ig production by MNC stimulated with IL-4. MNC were stimulated with IL-4 (800 U/ml), and various concentrations of IL-8 were added. After 14 d of culture, IgE and IgG4 (A) and IgM, IgG1, IgA, IgG2, and IgG3 (B) were determined. Values are means ± one SD of triplicate cultures from two experiments.

![Figure 2](image2.png)

**Figure 2.** Kinetics of the addition of IL-8 to IL-4–stimulated MNC. MNC were stimulated with IL-4 (800 U/ml), and IL-8 (1 μg/ml) was added at the initiation (day 0), or after 1–4 days of culture. As controls, MNC were cultured with IL-4 (800 U/ml) in the absence of IL-8; IL-8 (-). After 14 d of culture, IgE and IgG4 production were determined. Values are means ± one SD of triplicate cultures of IgE (●) and IgG4 (○).
Table 1. Specificity of the IL-8 Effect on IgE and IgG4 Production by MNC

| Factors                      | Expt. 1 | Expt. 2 | Expt. 3 |
|------------------------------|---------|---------|---------|
|                              | IgE     | IgG4    | IgE     | IgG4    | IgE     | IgG4    |
| Medium                       | 5.2     | 27.7    | 2.2     | 31.0    | 1.9     | 14.8    |
| IL-8                         | <0.2    | 3.0     | 0.6     | 2.1     | <0.2    | <0.6    |
| Anti-IL-8 mAb                | 6.2     | 31.2    | 3.0     | 40.4    | 2.7     | 17.2    |
| IL-8 + anti-IL-8 mAb         | 4.9     | 25.2    | 2.0     | 25.8    | 1.6     | 12.0    |
| IL-8 + control IgG1          | <0.2    | 3.6     | 0.7     | 3.4     | <0.2    | 0.5     |
| IL-8 + anti-IFN-γ mAb        | <0.2    | 4.2     | 0.9     | 3.5     | <0.2    | 0.9     |
| IL-8 + IL-5                  | <0.2    | 4.1     | 0.9     | 3.4     | <0.2    | 0.8     |
| IL-8 + IL-6                  | <0.2    | 4.5     | 1.0     | 3.2     | <0.2    | 0.9     |
| IFN-γ                        | <0.2    | 2.6     | 0.3     | 1.0     | <0.2    | <0.6    |
| Anti-IFN-γ mAb               | 7.2     | 37.6    | 3.1     | 43.0    | 2.0     | 20.8    |
| IFN-γ + anti-IFN-γ mAb       | 5.0     | 30.1    | 1.9     | 30.0    | 1.6     | 12.9    |
| IFN-γ + anti-IL-8 mAb        | <0.2    | 2.0     | 0.7     | 1.4     | <0.2    | 0.6     |

Tonsillar MNC were stimulated with IL-4 (800 U/ml), and cultured with indicated factors. IL-8 was used at 1 μg/ml, anti-IL-8 mAb at 10 μg/ml, control IgG1 at 10 μg/ml, anti-IFN-γ at 10 μg/ml, IL-5 at 100 ng/ml, IL-6 at 100 U/ml, and IFN at 1,000 U/ml. Values are means of triplicate cultures. SD were <15%.

Table 2. Effect of IL-8 on IgE and IgG4 Production by Purified B Cells Stimulated with IL-4 and Anti-CD40 Antibody

| Factors                      | Expt. 1 | Expt. 2 | Expt. 3 |
|------------------------------|---------|---------|---------|
|                              | IgE     | IgM     | IgE     | IgA     | IgE     | IgG4    |
| Medium                       | <0.2    | 38.1    | <0.2    | 5.0     | <0.2    | 0.8     |
| IL-8                         | <0.2    | 37.0    | <0.2    | 4.4     | <0.2    | 0.7     |
| IL-4 + anti-CD40             | 3.1     | 40.1    | 8.7     | 6.4     | 2.9     | 0.6     |
| IL-4 + anti-CD40 + IFN-γ     | 3.3     | 32.3    | 8.5     | 5.2     | 2.5     | 0.7     |
| IL-4 + anti-CD40 + IFN-α     | 3.0     | 36.4    | 9.1     | 5.5     | 3.1     | 0.7     |
| IL-4 + anti-CD40 + PGE₂      | 2.8     | 40.9    | 8.2     | 5.9     | 3.0     | 0.8     |
| IL-4 + anti-CD40 + IL-8      | <0.2    | 41.2    | 0.5     | 5.6     | 0.7     | 0.7     |
| IL-4 + anti-CD40 + IL-8 +    | 3.2     | 36.6    | 9.2     | 5.9     | 3.0     | 0.8     |
| anti-IL-8 mAb                |         |         |         |         |         |         |
| IL-4 + anti-CD40 + IL-8      | <0.2    | 41.2    | 0.6     | 5.6     | 0.8     | 0.7     |
| + control IgG1               |         |         |         |         |         |         |
| IL-4 + anti-CD40 + IL-8 +    | <0.2    | 42.2    | 0.8     | 6.1     | 0.8     | 0.8     |
| IL-8 + IL-5                  |         |         |         |         |         |         |
| IL-4 + anti-CD40 + IL-8 + IL-6 | <0.2    | 40.6    | 0.7     | 5.5     | 0.7     | 0.8     |

Purified B cells were cultured with indicated factors. IL-8 was used at 1 μg/ml, IL-4 at 800 U/ml, anti-CD40 antibody at 0.1 μg/ml, IFN-γ at 1,000 U/ml, IFN-α at 1,000 U/ml, PGE₂ at 10⁻⁶ M, anti-IL-8 mAb at 10 μg/ml, control mouse IgG1 at 10 μg/ml, IL-5 at 100 ng/ml, and IL-6 at 100 U/ml. Values are means of triplicate cultures. SD were <15%.
production by purified B cells. In contrast, addition of IL-8 inhibited IgE production without affecting IgM, IgA, or IgG4 production (Table 2). IL-8 also had no effect on IgG1, IgG2, or IgG3 production (data not shown). IL-8–induced inhibition of IgE production was blocked by anti–IL-8 mAb, but not by control IgG1. Addition of IL-5 (up to 100 ng/ml) or IL-6 (up to 100 U/ml) did not reverse the IL-8–induced inhibition of IgE production.

Discussion

We have demonstrated that IL-8 selectively inhibits IgE and IgG4 production in MNC stimulated with IL-4. Inhibition by IL-8 was specific, since it could be blocked by anti–IL-8 mAb but not by control mouse IgG1. Kinetic experiments showed that IL-8 had to be added at the initiation of the culture. Delayed addition of IL-8 after 1 d of culture had no effect. These results indicate that IL-8 inhibits the early activation step during IL-4 stimulation, and that the inhibition is not due to cytotoxicity. Although IFN-γ also inhibited IgE and IgG4 production in those cultures, the IL-8 effect was not mediated by IFN-γ, since IL-8–mediated inhibition was not blocked by anti–IFN-γ mAb, and conversely, the IFN-γ effect was not blocked by anti–IL-8 mAb. Moreover, IL-5 or IL-6, which enhanced IL-4–induced IgE production, did not reverse IL-8–induced inhibition of IgE production.

IL-8 also selectively inhibited IgE production by highly purified B cells stimulated with IL-4 and anti-CD40 antibody. In purified B cells, IL-8–induced inhibition of IgE production was specific and direct, since inhibition was not mediated through IFN-γ, IFN-α, or PGE2, which failed to inhibit IgE production. This is not surprising since they all inhibit IL-4–induced IgE production by MNC via interactions of T cells and B cells (1). Moreover, the IL-8 effect was blocked by anti–IL-8 mAb but not by control mouse IgG1, and was not reversed by IL-5 or IL-6. Taken together, these results indicate that IL-8 could inhibit IL-4–induced IgE production in both T cell–dependent and –independent systems, and the inhibition was not dependent on IFN-γ, IFN-α, IL-5, or IL-6.

Monocyte-derived IL-8 has been characterized and cloned as a neutrophil chemotaxin and activator (12). In addition to these activities, IL-8 is chemotactic for T cells (13), and induces histamine release by IL-3–primed basophils (14). IL-8 mRNA can be induced in endothelial cells, fibroblasts, epithelial cells, hepatoma cells, neutrophils, and T cells (17, 18). IL-8 receptors were detected on neutrophils, monocytes, lymphocytes, T cell and monoblast cell lines (19, 20). To our knowledge, this is the first report of a direct effect on B cells, resulting in inhibition of IgE production. Preliminary work in our laboratory showed that IL-8 also inhibits proliferation in human B cell line stimulated with IL-4 (Kimata et al., manuscript in preparation).

The exact mechanism of the IL-8–induced inhibition of IgE production is currently under investigation. This system will be very useful to dissect the inhibition of IgE regulation. The in vivo role of IL-8 in IgE production remains to be elucidated. It has been reported that IL-5, IL-6, or IFN-γ, which play an important role in IgE regulation in vitro, do not affect IgE regulation in vivo in atopic patients or in patients with hyper-IgE syndrome (21–23). It might be interesting to assess IL-8 levels in those patients. We are currently studying the effect of IL-8 on IgE production by B cells from atopic patients.

We wish to thank Dr. P. Peichl for production of, and M. Ceska for purification of, the anti–IL-8 mAb, and E. Wasserbauer for purification of IL-8.

This work was supported by a grant from the Ministry of Health and Welfare and a Grant-in-Aid for Scientific Research from the Ministry of Education, Science and Culture, Japan.

Address correspondence to H. Kimata, Department of Pediatrics, Kyoto University, 54, Kawahara-cho, Shogoin, Sakyo-ku, Kyoto 606, Japan.

Received for publication 11 May 1992 and in revised form 18 June 1992.

References

1. Pène, J., F. Rousset, F. Brière, J. Chrétine, J.-Y. Bonnefoy, H. Spits, T. Yokota, N. Arai, K. Arai, J. Banchereau, and J. De Vries. 1988. IgE production by normal human lymphocytes is induced by interleukin 4 and suppressed by interferon γ and α and prostaglandin E2. Proc. Natl. Acad. Sci. USA. 85:6880.
2. Pène, J., F. Rousset, F. Frère, I. Chrétien, J. Wideman, J.-Y. Bonnefoy, and J.E. De Vries. 1988. Interleukin 5 enhances interleukin 4–induced IgE production by normal human B cells.
3. Vercelli, D., H.H. Jabara, K. Arai, T. Yokota, and R.S. Geha. 1989. Endogenous IL-6 plays an obligatory role in IL-4 induced human IgE synthesis. Eur. J. Immunol. 19:1419.
4. Vercelli, D., H.H. Jabara, R.P. Lauener, and R.S. Geha. 1989. IL-4 inhibits the synthesis of IFN-γ and induces the synthesis of IgE in human mixed lymphocyte cultures. J. Immunol. 144:570.
5. Hart, P.H., G.F. Vitti, D.R. Burgess, G.A. Whitty, D.S. Piccoli,
and J.H. Hamilton. 1989. Potential antiinflammatory effects of interleukin 4: suppression of human monocyte tumor necrosis factor α, interleukin 1, and prostaglandin E2. Proc. Natl. Acad. Sci. USA. 86:3803.

Jabara, H.H., S.M. Fu, R.S. Geha, and D. Vercelli. 1990. CD40 and IgE: synergy between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J. Exp. Med. 172:1861.

Zhang, K., E.A. Clark, and A. Saxton. 1990. CD40 and IgE: synergy between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells for IgE production. J. Immunol. 146:1836.

Jabara, H.H., S.M. Fu, K.S. Geha, and D. Vercelli. 1990. CD40 and IgE: synergy between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells. J. Exp. Med. 172:1861.

Zhang, K., E.A. Clark, and A. Saxton. 1991. CD40 and IgE: synergy between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells via different signaling pathways. J. Immunol. 147:8.

Kimata, H., and A. Saxton. 1988. Subset of natural killer cells is induced by immune complexes to display Fc receptors for IgE and IgA and demonstrate isotype regulatory function. J. Clin. Invest. 82:160.

Kimata, H., A. Yoshida, C. Ishioka, and H. Mikawa. 1991. Effect of recombinant human erythropoietin on human IgE production in vitro. Clin. Exp. Immunol. 83:483.

Kimata, H., A. Yoshida, C. Ishioka, and H. Mikawa. 1991. Disodium cromoglycate (DSCG) selectively inhibits IgE production and enhances IgG4 production by human B cells in vitro. Clin. Exp. Immunol. 84:395.

Lindley, I., H. Aschauer, J.-M. Steiert, C. Lam, W. Brunowsky, E. Kownatzki, M. Thelen, P. Peveri, B. Dewalo, V. Von Tscharner, et al. 1988. Synthesis and expression in Escherichia coli of the gene encoding monocyte-derived neutrophil-activating factor: biological equivalence between natural and recombinant neutrophil-activating factor. Proc. Natl. Acad. Sci. USA. 85:3919.

Larsen, C.G., A.O. Anderson, E. Appella, J.J. Oppenheim, and K. Matsushima. 1989. The neutrophil-activating protein (NAP-1) is also chemotactic for T lymphocytes. Science (Wash. DC). 243:1464.

Dahinden, C.A., Y. Kurimoto, A.L. De Weck, I. Lindley, B. Dewald, and M. Baggiolini. 1989. The neutrophil-activating peptide NAP/NAP-1 induces histamine release and leukotriene release by interleukin 3-primed basophils. J. Exp. Med. 170:1787.

Gimbrone, Jr., M.A., M.S. Obin, A.F. Brock, E.A. Luis, P.E. Hass, C.A. Hébert, Y.K. Yip, D.W. Leung, D.G. Lowe, W.J. Kohr, et al. 1989. Endothelial interleukin-8: a novel inhibitor of leukocyte-endothelial interactions. Science (Wash. DC). 246:1601.

Standiford, T.J., R.M. Streiter, S.W. Chensue, J. Westwick, K. Kasahara, and S.L. Kunkel. 1990. IL-4 inhibits the expression of IL-8 from stimulated human monocytes. J. Immunol. 145:1439.

Baggiolini, M., and S.L. Kunkel. 1989. Neutrophil-activating peptide-1/interleukin 8, a novel cytokine that activates neutrophils. J. Clin. Invest. 84:1045.

Kunkel, S.L., R.M. Streiter, S.W. Chensue, M.A. Basha, T.J. Standiford, J. Ham, and D.G. Remick. 1990. Tumor necrosis factor-alpha, interleukin-8 and chemotactic cytokines. In Cytokines and Lipocortins in Inflammation and Differentiation. M. Melli, and L. Parente, editors. Alan R. Liss Inc., New York. pg. 433.

Besemer, J., A. Hujber, and B. Kuhn. 1989. Specific binding, internalization, and degradation of human neutrophil activating factor by human polymorphonuclear leukocytes. J. Biol. Chem. 264:17409.

Grob, P.M., E. David, T.C. Warren, R.P. DeLeon, P.R. Farina, and C.A. Homon. Characterization of a receptor for human monocyte-derived neutrophil chemotactic factor/interleukin-8. J. Biol. Chem. 265:8331.

Vercelli, D., H.H. Jabara, C. Cunningham-Rundles, J.S. Abrams, D.B. Lewis, J. Meyer, L.C. Schneider, D.Y.M. Leung, and R.S. Geha. 1991. Regulation of immunoglobulin (Ig)E synthesis in the hyper-IgE syndrome. J. Clin. Invest. 85:1666.

Lebedin, Y.S., L.A. Raudla, and A.G. Chuchalin. 1991. Serum levels of interleukin 4, interleukin 6 and interferon-gamma following in vivo isotype-specific activation of IgE synthesis in humans. Int. Arch. Allergy. Appl. Immunol. 96:92.

Classen, J.J., A.D. Levine, S.E. Schiff, and R.H. Buckley. 1991. Mononuclear cells from patients with the hyper-IgE syndrome produce little IgE when they are stimulated with recombinant human interleukin-4. J. Allergy. Clin. Immunol. 88:713.